Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Ovarian carcinosarcoma is a rare subtype of this disease that has not been thoroughly investigated. The aim of this study was to evaluate the prognostic factors and out comes in patients with ovarian carcinosarcoma. Methods: All patients with histologically confirmed ovarian carcinosarcoma who were treated at Cheil General Hospital and Women’s Healthcare Center between January 2000 and December 2015 were identified and analyzed. Data were extracted from medical records, and statistical analyses were performed to determine correlations between clinicopathological parameters and survival outcomes. Results: Of the 822 patients diagnosed with ovarian cancer over 16 years, 11 (1.3%) had ovarian carcinosarcoma histology. Every patient underwent surgery as the initial treatment followed by intravenous adjuvant chemotherapy. Only 18.1% of cases were early stage (I or II) while 81.8% were advanced stage (III or IV) according to the FIGO (International Federation of Gynecology and Obstetrics) classification. Six cases were of the homologous subtype (54.5%) and five were of the heterologous subtype (45.5%). There was no significant difference in survival according to stage (P=0.24). The heterologous subtype and residual disease were associated with poor disease-free survival (P=0.02 and P=0.04) and overall survival (P=0.02 and P=0.04), On multivariate analysis, the histological subtype was an independent prognostic factor (P=0.02). Conclusion: Optimal cytoreduction without gross residual disease and a homologous subtype are favorable prognostic factors in terms of disease relapse and survival.
Abstract
Objective: Ovarian carcinosarcoma is a rare subtype of this disease that has not been thoroughly investigated. The aim of this study was to evaluate the prognostic factors and out comes in patients with ovarian carcinosarcoma. Methods: All patients with histologically confirmed ovarian carcinosarcoma who were treated at Cheil General Hospital and Women’s Healthcare Center between January 2000 and December 2015 were identified and analyzed. Data were extracted from medical records, and statistical analyses were performed to determine correlations between clinicopathological parameters and survival outcomes. Results: Of the 822 patients diagnosed with ovarian cancer over 16 years, 11 (1.3%) had ovarian carcinosarcoma histology. Every patient underwent surgery as the initial treatment followed by intravenous adjuvant chemotherapy. Only 18.1% of cases were early stage (I or II) while 81.8% were advanced stage (III or IV) according to the FIGO (International Federation of Gynecology and Obstetrics) classification. Six cases were of the homologous subtype (54.5%) and five were of the heterologous subtype (45.5%). There was no significant difference in survival according to stage (P=0.24). The heterologous subtype and residual disease were associated with poor disease-free survival (P=0.02 and P=0.04) and overall survival (P=0.02 and P=0.04), On multivariate analysis, the histological subtype was an independent prognostic factor (P=0.02). Conclusion: Optimal cytoreduction without gross residual disease and a homologous subtype are favorable prognostic factors in terms of disease relapse and survival.
참고문헌 (19)
- Ferlay J, "Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Silasi DA, "Carcinosarcoma of the ovary", Int J Gynecol Cancer, 18, pp.22~29 (2008)
- George EM, "Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome", Gynecol Oncol, 131, pp.42~45 (2013)
- Jin Z, "Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis", Int J Gynecol Pathol, 22, pp.368~373 (2003)
- Harris MA, "Carcinosarcoma of the ovary", Br J Cancer, 88, pp.654~657 (2003)
- Rauh-Hain JA, "Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis", Gynecol Oncol, 131, pp.46~51 (2013)
- Haruko Iwase, "Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients", Journal of Gynecologic Oncology, 26(4), pp.303~310 (2015), 대한부인종양학회
- Bicher A, "Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy", Obstet Gynecol, 85, pp.735~739 (1995)
- Brown E, "Carcinosarcoma of the ovary: 19years of prospective data from a single center", Cancer, 100, pp.2148~2153 (2004)
- Morrow CP, "A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a Gynecologic Oncology Group study", Gynecol Oncol, 18, pp.278~292 (1984)
- Chang J, "Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients", Ann Oncol, 6, pp.755~758 (1995)
- Muller M, "Carcinosarcoma of the ovary", J Gynecol Obstet Biol Reprod (Paris), 36, pp.399~402 (2007)
- Rauh-Hain JA, "Carcinosarcoma of the ovary: a case-control study", Gynecol Oncol, 121, pp.477~481 (2011)
- Loizzi V, "Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature", Oncology, 80, pp.102~106 (2011)
- Sood AK, "Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction", Cancer, 82, pp.1731~1737 (1998)
- Mok JE, "Malignant mixed Mullerian tumors of the ovary:experience with cytoreductive surgery and platinumbased combination chemotherapy", Int J Gynecol Cancer, 16, pp.101~105 (2006)
- Amant F, "Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis", Gynecol Oncol, 90, pp.372~377 (2003)
- Leiser AL, "Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience", Gynecol Oncol, 105, pp.657~661 (2007)
- Muntz HG, "Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy", Cancer, 76, pp.1209~1213 (1995)